# Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms

> **NCT01021332** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 1067 (actual)

## Conditions studied

- Lower Urinary Tract Symptoms
- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
- **DRUG:** tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)

## Key facts

- **NCT ID:** NCT01021332
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-26
- **Primary completion:** 2011-12-14
- **Final completion:** 2011-12-14
- **Target enrollment:** 1067 (ACTUAL)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01021332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01021332, "Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01021332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*